<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00026299</url>
  </required_header>
  <id_info>
    <org_study_id>11089A</org_study_id>
    <secondary_id>UCCRC-11089</secondary_id>
    <secondary_id>NCI-3857</secondary_id>
    <nct_id>NCT00026299</nct_id>
  </id_info>
  <brief_title>Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer</brief_title>
  <official_title>A Phase I/ Randomized Phase II Trial Of Oxaliplatin (NSC #266046) With Or Without ZD 1839 (NSC # 715055) In Patients With Advanced Colorectal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Biological therapies such as gefitinib may interfere with the&#xD;
      growth of the tumor cells and slow the growth of colorectal cancer. Combining chemotherapy&#xD;
      with gefitinib may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to compare the effectiveness of chemotherapy with or without&#xD;
      gefitinib in treating patients who have metastatic or locally recurrent colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the recommended phase II dose of gefitinib when administered in combination&#xD;
           with oxaliplatin in patients with metastatic or locally recurrent colorectal cancer.&#xD;
&#xD;
        -  Determine the dose-limiting toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Compare the time to progression, objective response rate, and median and overall&#xD;
           survival in patients treated with oxaliplatin with or without gefitinib.&#xD;
&#xD;
        -  Compare the toxicity of these regimens in these patients.&#xD;
&#xD;
      OUTLINE: This is a phase I dose-escalation study of gefitinib followed by a phase II&#xD;
      randomized, multicenter study. Patients are stratified according to ECOG performance status&#xD;
      (0 vs 1-2).&#xD;
&#xD;
        -  Phase I: Patients receive oxaliplatin IV over 2 hours on day 1 and oral gefitinib once&#xD;
           daily on days 1-21. Treatment repeats every 21 days in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of gefitinib until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
        -  Phase II: Patients are randomized to one of two treatment arms.&#xD;
&#xD;
             -  Arm I: Patients receive oxaliplatin IV over 2 hours on day 1.&#xD;
&#xD;
             -  Arm II: Patients receive oxaliplatin as in arm I and oral gefitinib once daily at&#xD;
                the MTD on days 1-21.&#xD;
&#xD;
      In both arms, treatment repeats every 21 days for up to 6 courses in the absence of disease&#xD;
      progression or unacceptable toxicity. Patients in arm II with stable or responding disease&#xD;
      after 6 courses may continue to receive gefitinib alone until disease progression.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 77 patients (9 for phase I and 68 for phase II) will be&#xD;
      accrued for this study within 12-14 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2001</start_date>
  <completion_date type="Actual">February 2005</completion_date>
  <primary_completion_date type="Actual">December 2002</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended dose of ZD1839 in combination with oxaliplatin</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Phase 2: Oxaliplatin plus ZD1839</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxaliplatin will be administered by IV infusion once every 21 days at a fixed dose of 130 mg/m2 and ZD1839 will be taken orally at a dose of 250 mg or 500 mg daily (as determined during phase 1). Subjects can continue to receive the combination for 6 cycles (each cycle is 21 days). After 6 cycles of the combination, subjects can continue to take ZD1839 alone until their cancer worsens.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Oxaliplatin alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxaliplatin will be administered by IV infusion once every 21 days at a fixed dose of 130 mg/m2 for up to 6 cycles. Each cycle will last 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I: Oxaliplatin with ZD1839</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxaliplatin will be administered by IV infusion once every 21 days at a fixed dose of 130 mg/m2. ZD1839 will be taken orally at a dose of 250 mg or 500 mg daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZD1839</intervention_name>
    <arm_group_label>Phase 2: Oxaliplatin plus ZD1839</arm_group_label>
    <arm_group_label>Phase I: Oxaliplatin with ZD1839</arm_group_label>
    <other_name>gefitinib, Iressa ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <arm_group_label>Phase 2: Oxaliplatin alone</arm_group_label>
    <arm_group_label>Phase 2: Oxaliplatin plus ZD1839</arm_group_label>
    <arm_group_label>Phase I: Oxaliplatin with ZD1839</arm_group_label>
    <other_name>Eloxatin ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the colon or rectum that&#xD;
             is not amenable to potentially curative surgical resection&#xD;
&#xD;
          -  Metastatic or locally recurrent disease&#xD;
&#xD;
          -  Tumor in liver or lung accessible to needle biopsy by ultrasound or CT scan guidance&#xD;
&#xD;
          -  At least 1 measurable lesion&#xD;
&#xD;
               -  At least 20 mm by conventional techniques, including physical examination, CT&#xD;
                  scan, or MRI OR&#xD;
&#xD;
               -  At least 10 mm by spiral CT scan&#xD;
&#xD;
               -  Lesions on colonoscopic examination or barium studies, bone metastases, CNS&#xD;
                  lesions, and ascites are not considered measurable&#xD;
&#xD;
          -  Failed prior therapy with fluorouracil, leucovorin calcium, and irinotecan given&#xD;
             either sequentially or in combination&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  AST/ALT no greater than 2.5 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No peripheral neuropathy greater than grade 1&#xD;
&#xD;
          -  No other concurrent uncontrolled illness that would preclude study&#xD;
&#xD;
          -  No concurrent psychiatric illness or social situation that would preclude study&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No prior allergic reaction to compounds of similar chemical or biologic composition to&#xD;
             oxaliplatin or gefitinib&#xD;
&#xD;
          -  No other concurrent malignancy except non-melanoma skin cancer or carcinoma in situ of&#xD;
             the cervix unless considered to be at less than 30% risk of relapse after completion&#xD;
             of therapy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior epidermal growth factor inhibitor&#xD;
&#xD;
          -  At least 24 hours since prior colony-stimulating factors&#xD;
&#xD;
          -  No concurrent colony-stimulating factors during first course of study therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No more than 2 prior chemotherapy regimens for metastatic disease&#xD;
&#xD;
          -  Prior adjuvant chemotherapy allowed&#xD;
&#xD;
          -  At least 4 weeks since prior cytotoxic chemotherapy and recovered&#xD;
&#xD;
          -  No prior cisplatin or oxaliplatin&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 30 days since prior investigational agents&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  No concurrent anti-retroviral therapy for HIV&#xD;
&#xD;
          -  No other concurrent investigational or commercial agents or therapies for malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hedy L. Kindler, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louis A. Weiss Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Decatur Memorial Hospital Cancer Care Institute</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evanston Northwestern Health Care</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ingalls Memorial Hospital</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LaGrange Memorial Hospital</name>
      <address>
        <city>LaGrange</city>
        <state>Illinois</state>
        <zip>60525</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153-5589</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology/Hematology Associates of Central Illinois, P.C.</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Illinois Hematology Oncology Center</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Medical Oncology and Hematology, Inc.</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46885-5099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital of South Bend</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Care Associates, P.L.L.C.</name>
      <address>
        <city>Saint Joseph</city>
        <state>Michigan</state>
        <zip>49085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Kindler HL, Friberg G, Skoog L, Wade-Oliver K, Vokes EE. Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer. Am J Clin Oncol. 2005 Aug;28(4):340-4.</citation>
    <PMID>16062074</PMID>
  </results_reference>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>November 9, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 4, 2013</last_update_submitted>
  <last_update_submitted_qc>September 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

